Replies to post #130493 on Biotech Values

[DewDiligence]

Teva's rate seems consistent and within their historical ranges.

The interest rates on Teva’s new bonds are consistent with what Teva paid when market interest rates were higher. In a relative sense, Teva is paying more than it has in a long time because of the threat to Copaxone and the leveraging of the balance sheet to acquire CEPH.

[DewDiligence]

What did surprise me was that both zmh and teva have better deals than Amgen.

AMGN is paying a lot in a relative sense because its debt issuance is for the specific purpose of buying back stock.